Literature DB >> 23178566

Alzheimer's disease: critical notes on the history of a medical concept.

Jesus Ramirez-Bermudez1.   

Abstract

It is generally accepted that Alois Alzheimer, the German neuropathologist and clinician, discovered the disease that carries his name, after the clinicopathological study of a 51-year-old woman named Auguste D. who presented a dementia syndrome. The pathological study of the brain revealed the presence of neurofibrillary tangles and senile plaques. Emil Kraepelin coined the eponym Alzheimer's disease in the 8th edition of his textbook Clinical Psychiatry. However, several critical aspects of this history have been pointed out by historians of psychiatry. This article provides a narrative of the best-known facts leading to the formation of the original concept but also presents an informed discussion of the main critical points: 1. The descriptions of senile plaques and neurofibrillary tangles in the context of dementia before Alzheimer's report. 2. The presence or absence of arteriosclerotic changes in the brain of Auguste D. 3. The presence of noncognitive symptoms in August D. 4. The influence of social, political and economic issues in the formation and selection of medical concepts.
Copyright © 2012 IMSS. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23178566     DOI: 10.1016/j.arcmed.2012.11.008

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  15 in total

1.  Progress in Human Brain Banking in China.

Authors:  Chao Ma; Ai-Min Bao; Xiao-Xin Yan; Dick F Swaab
Journal:  Neurosci Bull       Date:  2019-03-07       Impact factor: 5.203

Review 2.  Molecular Anti-inflammatory Mechanisms of Retinoids and Carotenoids in Alzheimer's Disease: a Review of Current Evidence.

Authors:  Niyaz Mohammadzadeh Honarvar; Ahmad Saedisomeolia; Mina Abdolahi; Amir Shayeganrad; Gholamreza Taheri Sangsari; Babak Hassanzadeh Rad; Gerald Muench
Journal:  J Mol Neurosci       Date:  2016-11-18       Impact factor: 3.444

Review 3.  Alzheimer's Disease Therapeutic Approaches.

Authors:  Maria Revi
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 4.  Long noncoding RNAs and Alzheimer's disease.

Authors:  Qiong Luo; Yinghui Chen
Journal:  Clin Interv Aging       Date:  2016-06-29       Impact factor: 4.458

5.  Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer's disease.

Authors:  Justyna Sosna; Stephan Philipp; Ricardo Albay; Jorge Mauricio Reyes-Ruiz; David Baglietto-Vargas; Frank M LaFerla; Charles G Glabe
Journal:  Mol Neurodegener       Date:  2018-03-01       Impact factor: 14.195

6.  Mitofusin-2 knockdown increases ER-mitochondria contact and decreases amyloid β-peptide production.

Authors:  Nuno Santos Leal; Bernadette Schreiner; Catarina Moreira Pinho; Riccardo Filadi; Birgitta Wiehager; Helena Karlström; Paola Pizzo; Maria Ankarcrona
Journal:  J Cell Mol Med       Date:  2016-05-20       Impact factor: 5.310

Review 7.  Role of berberine in Alzheimer's disease.

Authors:  Zhiyou Cai; Chuanling Wang; Wenming Yang
Journal:  Neuropsychiatr Dis Treat       Date:  2016-10-03       Impact factor: 2.570

Review 8.  Alzheimer's Disease: From Genetic Variants to the Distinct Pathological Mechanisms.

Authors:  Qiying Sun; Nina Xie; Beisha Tang; Rena Li; Yong Shen
Journal:  Front Mol Neurosci       Date:  2017-10-06       Impact factor: 5.639

Review 9.  Anti-neuroinflammatory Potential of Natural Products in Attenuation of Alzheimer's Disease.

Authors:  Bushra Shal; Wei Ding; Hussain Ali; Yeong S Kim; Salman Khan
Journal:  Front Pharmacol       Date:  2018-05-29       Impact factor: 5.810

Review 10.  Iron metabolism in diabetes-induced Alzheimer's disease: a focus on insulin resistance in the brain.

Authors:  Ji Yeon Chung; Hyung-Seok Kim; Juhyun Song
Journal:  Biometals       Date:  2018-07-24       Impact factor: 2.949

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.